Cardiometabolic Considerations

CE / CME

Individualizing ART With Cardiometabolic Considerations

Nurses: 0.75 Nursing contact hour

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: July 10, 2024

Expiration: July 09, 2025

Activity

Progress
1 2
Course Completed

References

  1. European AIDS Clinical Society. Guidelines. V12.0. October 2023. eacsociety.org/media/guidelines-12.0.pdf. Accessed June 26, 2024.
  2. HIV.gov. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new. Accessed June 26, 2024.
  3. International Antiviral Society-USA. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA Panel. iasusa.org/2022/11/30/antiretroviral-drugs-treatment-prevention-hiv-infection-adults-2020-recommendations-of-the-international-antiviral-society-usa-panel-2022/. Accessed June 26, 2024.
  4. Neesgaard B, Greenberg L, Miro JM, et al. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. Lancet HIV. 2022;9:e474-e485.
  5. Surial B, Chammartin F, Damas J, et al. Impact of integrase inhibitors on cardiovascular disease events in people with human immunodeficiency virus starting antiretroviral therapy. Clin Infect Dis. 2023;77:729-737.
  6. Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: Risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71:1379-1389.
  7. HIV-Assist. hivassist.com/. Accessed June 26, 2024.
  8. McCann K, Shah S, Hindley L, et al. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. AIDS. 2021;35:1657-1665.
  9. O'Halloran JA, Sahrmann J, Parra-Rodriguez L, et al. Integrase strand transfer inhibitors are associated with incident diabetes mellitus in people with human immunodeficiency virus. Clin Infect Dis. 2022;75:2060-2065.
  10. McComsey GA, Emond B, Shah A, et al. Association between weight gain and the incidence of cardiometabolic conditions among people living with HIV-1 at high risk of weight gain initiated on antiretroviral therapy. Infect Dis Ther. 2022;11:1883-1899.
  11. McComsey GA, Sattar A, Albar Z, et al. Effects of semaglutide on adipose tissue in HIV-associated lipohypertrophy. Presented at: IDWeek; 2023. Abstract 1984.
  12. Lake JE, Kitch DW, Kantor A, et al. Semaglutide reduces metabolic-associated steatotic liver disease in people with HIV: The SLIM LIVER. Presented at: 31st annual Conference on Retroviruses and Opportunistic Infections (CROI); 2024. Abstract 159.
  13. Grinspoon S. Key REPRIEVE results and the utility of statins among people living with HIV: What have we learned? Presented at: 12th International AIDS Society (IAS); 2023. Symposium session: SY06.
  14. Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023;389:687-699.
  15. Feinstein MJ. HIV and cardiovascular disease: From insights to interventions. Top Antivir Med. 2021;29:407-411.